Form 8-K - Current report:
SEC Accession No. 0001213900-24-056807
Filing Date
2024-06-28
Accepted
2024-06-27 20:32:35
Documents
16
Period of Report
2024-06-27
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0208584-8k_inmed.htm   iXBRL 8-K 32316
2 OPINION OF NORTON ROSE FULBRIGHT CANADA LLP ea020858401ex5-1_inmed.htm EX-5.1 14287
3 AMENDMENT NO. 1, DATED JUNE 27, 2024, TO THE AT THE MARKET OFFERING AGREEMENT, D ea020858401ex10-1_inmed.htm EX-10.1 22829
7 GRAPHIC ex5-1_001.jpg GRAPHIC 13740
  Complete submission text file 0001213900-24-056807.txt   275899

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE inm-20240627.xsd EX-101.SCH 3021
5 XBRL LABEL FILE inm-20240627_lab.xml EX-101.LAB 34240
6 XBRL PRESENTATION FILE inm-20240627_pre.xml EX-101.PRE 22364
20 EXTRACTED XBRL INSTANCE DOCUMENT ea0208584-8k_inmed_htm.xml XML 3795
Mailing Address SUITE 310, 815 W. HASTINGS STREET VANCOUVER A1 V6C 1B4
Business Address SUITE 310, 815 W. HASTINGS STREET VANCOUVER A1 V6C 1B4 (604) 669-7207
InMed Pharmaceuticals Inc. (Filer) CIK: 0001728328 (see all company filings)

EIN.: 000000000 | State of Incorp.: A1 | Fiscal Year End: 0630
Type: 8-K | Act: 34 | File No.: 001-39685 | Film No.: 241081046
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)